Scarica l'app Stockscreener
12.80
3.54%
-0.47
Dopo l'orario di chiusura:
12.81
0.010
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché WVE Giù?
Forum
Previsione
Precedente Chiudi:
$13.27
Aprire:
$13.19
Volume 24 ore:
3.20M
Relative Volume:
0.49
Capitalizzazione di mercato:
$2.38B
Reddito:
$93.95M
Utile/perdita netta:
$-129.87M
Rapporto P/E:
-14.22
EPS:
-0.9
Flusso di cassa netto:
$-202.88M
1 W Prestazione:
+0.39%
1M Prestazione:
-7.98%
6M Prestazione:
+51.48%
1 anno Prestazione:
+17.32%
Intervallo 1D:
$12.51
$13.23
Intervallo di 1 settimana:
$12.51
$14.15
Portata 52W:
$5.28
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Nome
Wave Life Sciences Ltd
Settore
Industria
Telefono
617-949-2900
Indirizzo
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
12.80 | 2.47B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-05 | Iniziato | BofA Securities | Buy |
| 2025-12-12 | Reiterato | Wedbush | Outperform |
| 2025-12-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-04 | Iniziato | Canaccord Genuity | Buy |
| 2025-07-28 | Iniziato | Oppenheimer | Outperform |
| 2025-07-16 | Iniziato | Citigroup | Buy |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Wedbush | Outperform |
| 2025-02-25 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Ripresa | JP Morgan | Overweight |
| 2024-09-19 | Iniziato | B. Riley Securities | Buy |
| 2024-09-09 | Iniziato | JP Morgan | Overweight |
| 2024-05-15 | Iniziato | Wells Fargo | Overweight |
| 2023-12-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Raymond James | Outperform |
| 2023-05-24 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-07-15 | Iniziato | Cowen | Market Perform |
| 2019-04-17 | Reiterato | H.C. Wainwright | Buy |
| 2018-08-07 | Iniziato | Stifel | Buy |
| 2018-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2017-02-15 | Iniziato | H.C. Wainwright | Buy |
| 2016-11-10 | Ripresa | Leerink Partners | Outperform |
| 2015-12-07 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-07 | Iniziato | Jefferies | Buy |
| 2015-12-07 | Iniziato | Leerink Partners | Outperform |
| 2015-12-07 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
Mostra tutto
Wave Life Sciences Ltd Borsa (WVE) Ultime notizie
WAVE Life Sciences (NASDAQ:WVE) Given New $27.00 Price Target at Wells Fargo & Company - MarketBeat
WVE Stock Update: Wells Fargo Adjusts Price Target Amidst Steady Ratings | WVE Stock News - GuruFocus
Paul Bolno Sells 10,480 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 1,883 Shares of Stock - MarketBeat
Kyle Moran Sells 3,588 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
(02/11/26) Top Picks 2026: Wave Life Sciences Ltd. (WVE) - moneyshow.com
Published on: 2026-02-10 01:59:11 - baoquankhu1.vn
Wave Life Sciences (WVE) regains rights to potential rare genetic disorder treatment - MSN
The Bull Case For Wave Life Sciences (WVE) Could Change Following WVE-006 Rights Reversion And FDA Talks - Yahoo Finance
Assessing Wave Life Sciences (WVE) Valuation After A 7x Three Year Total Return - Yahoo Finance
Why The Wave Life Sciences WVE Story Is Shifting After New RNA And AATD Updates - Yahoo Finance
Will Regaining Full Rights to WVE-006 and Pursuing FDA Fast Track Change Wave Life Sciences' (WVE) Narrative - simplywall.st
How (WVE) Movements Inform Risk Allocation Models - Stock Traders Daily
Wave Life Sciences (WVE) Regains Rights to Potential Rare Genetic Disorder Treatment - Finviz
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Wave Life Sciences receives back rights to AATD therapy from GSK - MSN
13 Best Revenue Growth Stocks to Buy Right Now - Insider Monkey
WAVE Life Sciences (NASDAQ:WVE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
WAVE Life Sciences (NASDAQ:WVE) Now Covered by Bank of America - MarketBeat
WVE Sees Analyst Rating Boost with Raised Price Target | WVE Stock News - GuruFocus
Assessing Wave Life Sciences (WVE) Valuation After Regaining Global Rights To WVE-006 From GSK - Sahm
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Wave Life Sciences (WVE) and Arcellx Inc (ACLX) - The Globe and Mail
Wave Life Sciences Ltd. (WVE): Analyst Consensus Highlights 143.73% Potential Upside for Biotech Innovator - DirectorsTalk Interviews
Wave Life Sciences price target raised to $50 from $47 at Clear Street - Yahoo Finance
WVE Sees Price Target Boost: Canaccord Genuity Adjusts to $43.00 - GuruFocus
Wave Life Sciences Regains Full Rights to WVE-006 from GSK - intellectia.ai
WAVE Life Sciences stock price target raised to $43 from $40 at Canaccord - Investing.com Australia
WAVE Life Sciences stock rating reiterated at Buy by H.C. Wainwright - Investing.com India
Wave Life Sciences regains rights to AATD therapy WVE-006 from GSK - Investing.com Nigeria
Wave Life Sciences regains rights to AATD therapy WVE-006 from GSK By Investing.com - Investing.com South Africa
WAVE Life Sciences stock rating reiterated by Raymond James on regained drug rights - Investing.com Australia
Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path - Benzinga
Clear Street raises WAVE Life Sciences stock price target to $50 on AATD program - Investing.com Nigeria
Wave Life Sciences stock rises after regaining full rights to AATD therapy By Investing.com - Investing.com South Africa
Wave Life Sciences stock rises after regaining full rights to AATD therapy - Investing.com India
Wave Life Sciences (WVE) Reclaims Rights to AATD Asset WVE-006 - GuruFocus
Wave Life Sciences plans to accelerate regulatory engagement with full control of WVE-006 - marketscreener.com
Wave Life Sciences Regains WVE-006 Rights, Plans Accelerated Path - TipRanks
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency - The Manila Times
Wave Life Sciences Ltd Accelerates Regulatory Engagement for WVE-006 - TradingView
Wave RNA drug for rare lung and liver disease heads for FDA talks - Stock Titan
How Investors May Respond To Wave Life Sciences (WVE) Expanding PRISM RNA Platform Via Big-Pharma Partnerships - Sahm
Market Outlook: Does CBTJ stock reflect fundamentalsJuly 2025 Volume & High Accuracy Investment Entry Signals - baoquankhu1.vn
Federated Hermes Inc. Has $27.46 Million Position in WAVE Life Sciences Ltd. $WVE - MarketBeat
WAVE Life Sciences (NASDAQ:WVE) Stock Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
Wave Life Sciences Ltd. (WVE) Growth Potential: Analysts Predict 141% Upside - DirectorsTalk Interviews
Trading Systems Reacting to (WVE) Volatility - Stock Traders Daily
Aug Outlook: Will Standard BioTools Inc stock recover after earningsPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
Buyback Watch: Will Wave Life Sciences Ltd outperform small cap indexes2025 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn
Moving Averages: Is Wave Life Sciences Ltd stock suitable for long term investingWeekly Stock Report & Advanced Technical Signal Analysis - baoquankhu1.vn
Emerald Mutual Fund Advisers Trust Sells 171,427 Shares of WAVE Life Sciences Ltd. $WVE - MarketBeat
Wave Life Sciences Ltd Azioni (WVE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Wave Life Sciences Ltd Azioni (WVE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):